Last reviewed · How we verify

Xtampza ER — Competitive Intelligence Brief

Xtampza ER (Xtampza ER) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic, abuse-deterrent formulation. Area: Pain Management.

marketed Opioid analgesic, abuse-deterrent formulation Mu-opioid receptor (μ-OR) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Xtampza ER (Xtampza ER) — University of Alabama at Birmingham. Xtampza ER is an extended-release formulation of oxycodone that provides prolonged opioid analgesia through mu-opioid receptor agonism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xtampza ER TARGET Xtampza ER University of Alabama at Birmingham marketed Opioid analgesic, abuse-deterrent formulation Mu-opioid receptor (μ-OR)
OxyNEO® OxyNEO® Centre for Addiction and Mental Health marketed Opioid analgesic, abuse-deterrent formulation Mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic, abuse-deterrent formulation class)

  1. Centre for Addiction and Mental Health · 1 drug in this class
  2. University of Alabama at Birmingham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xtampza ER — Competitive Intelligence Brief. https://druglandscape.com/ci/xtampza-er. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: